Pfizer Recalls Lots of Ambaro (valsartan and amlodipine besylate salt) for its Carcinogenic Effects in Japan

 Pfizer Recalls Lots of Ambaro (valsartan and amlodipine besylate salt) for its Carcinogenic Effects in Japan

Pfizer Recalls Lots of Ambaro (valsartan and amlodipine besylate salt) for its Carcinogenic Effects in Japan

Shots:

  • The voluntary Class I recall of Ambaro is due to presence of trace amounts of N-nitrosodiethylamine (NDEA) & N-nitrosodimethylamine (NDMA) in marketed b/w 3 Dec,2018 to 23 Jan,2019
  • The recall is for no. of 763,000 tablets, manufactured in April to July 2018 which contained cancer causing substance, also examined by WHO
  • Additionally, Teva and Mylan initiated their recalls in Jan,2019 and Dec,2018 respectively for valsartan lots used as anti-hypertensive medication

Click here to read full press release/ article | Ref: Pfizer | Image: Wall Street Journal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post